Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

RemeGen Co stock price, quote, forecast and news

9995.HK
CNE1000048G6
A2QGM4

Price

11.59
Today +/-
+0.07
Today %
+4.80 %
P

RemeGen Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the RemeGen Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the RemeGen Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the RemeGen Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze RemeGen Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

RemeGen Co Stock Price History

DateRemeGen Co Price
9/11/202411.59 undefined
9/10/202411.05 undefined
9/9/202411.37 undefined
9/5/202411.35 undefined
9/4/202411.09 undefined
9/3/202411.21 undefined
9/2/202410.95 undefined
8/30/202411.33 undefined
8/29/202411.16 undefined
8/28/202410.70 undefined
8/27/202411.07 undefined
8/26/202411.31 undefined
8/23/202410.89 undefined
8/22/202411.45 undefined
8/21/202412.83 undefined
8/20/202412.90 undefined
8/19/202413.31 undefined
8/16/202413.30 undefined
8/15/202413.16 undefined

RemeGen Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into RemeGen Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by RemeGen Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects RemeGen Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of RemeGen Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into RemeGen Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing RemeGen Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on RemeGen Co’s growth potential.

RemeGen Co Revenue, EBIT and net profit per share

DateRemeGen Co RevenueRemeGen Co EBITRemeGen Co Net Income
2029e6.76 B undefined0 undefined0 undefined
2028e5.69 B undefined1.79 B undefined0 undefined
2027e4.43 B undefined543.43 M undefined0 undefined
2026e3.17 B undefined-122.09 M undefined-152.02 M undefined
2025e2.28 B undefined-730.66 M undefined-838.51 M undefined
2024e1.66 B undefined-1.21 B undefined-1.4 B undefined
20231.08 B undefined-1.52 B undefined-1.51 B undefined
2022772.11 M undefined-1.08 B undefined-998.83 M undefined
20211.42 B undefined238.8 M undefined276.3 M undefined
20200 undefined-670.2 M undefined-697.8 M undefined
20190 undefined-386.4 M undefined-430.3 M undefined
201811.3 M undefined-231.4 M undefined-269.9 M undefined

RemeGen Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e
0.01001.420.771.081.662.283.174.435.696.76
-----45.7540.1652.9638.0138.6240.0228.4518.77
18.18--95.2964.7776.25------
0001.360.50.83000000
-0.23-0.39-0.670.24-1.08-1.52-1.21-0.73-0.120.541.790
-2,100.00--16.73-139.25-140.02-72.93-31.96-3.8512.2531.47-
-269-430-697276-998-1,511-1,400-838-152000
-59.8562.09-139.60-461.5951.40-7.35-40.14-81.86---
478.4478.4408.1487.4531.29539.72000000
------------
Details

Keystats

ⓘ

Revenue and Growth

The RemeGen Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the RemeGen Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
201820192020202120222023
           
0.010.032.771.762.070.73
111.107.1202.03297.68
3.516.736.128.7101.41175.79
29.731.266.2280.3522.67741.56
15.754106.5227316.85287.35
0.070.142.982.33.212.23
0.40.470.941.732.663.04
1011.412.912.181.1998.23
31.147.560.654.700
2.92.15.113.155.86143.78
000000
24.219.9121.252.89.4620.85
0.470.551.141.862.813.3
0.530.694.124.166.025.53
           
00489.8489.8544.26544.26
0.070.173.713.716.236.24
-568.3-402.1-605-309.5-1,342.28-2,853.51
0.10-0.35.69.16.87
01.40.70.3-1.22-57.91
-0.5-0.233.593.95.443.88
16.767.762.6159.3108.87125.34
15.529.358.8114.4138.31224.2
963.5698.4158.7290.3447.87416.69
060108.10121.75301.45
1.11.64352.560.1560.44
10.860.430.620.881.13
3.43.846.650.3104.88915.26
000.70.30.041.51
2960.644.545.859.0246.08
32.464.491.896.4163.94962.85
1.030.920.520.711.042.09
0.530.694.124.616.485.97
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of RemeGen Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand RemeGen Co's financial health and stability.

Assets

RemeGen Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that RemeGen Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of RemeGen Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into RemeGen Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20182019202020212022
-269-430-6972760
2242771200
00000
7755-114-125-1,240
414975-70
0897250
0000174
-128-282-660263-1,260
-83-65-445-617-752
-77-95-479-637-851
6-29-33-20-98
00000
206406-531-1570
003.77-0.450
0.210.413.9-0.632.42
000.66-0.022.42
00000
00.032.73-1.010.12
-211.7-347.9-1,105.7-353.7-2,013.22
00000

RemeGen Co stock margins

The RemeGen Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of RemeGen Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for RemeGen Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the RemeGen Co's sales revenue. A higher gross margin percentage indicates that the RemeGen Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the RemeGen Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the RemeGen Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the RemeGen Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the RemeGen Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the RemeGen Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

RemeGen Co Margin History

RemeGen Co Gross marginRemeGen Co Profit marginRemeGen Co EBIT marginRemeGen Co Profit margin
2029e76.24 %0 %0 %
2028e76.24 %31.47 %0 %
2027e76.24 %12.26 %0 %
2026e76.24 %-3.86 %-4.8 %
2025e76.24 %-31.99 %-36.71 %
2024e76.24 %-72.98 %-84.64 %
202376.24 %-139.9 %-139.55 %
202264.77 %-139.28 %-129.36 %
202195.28 %16.77 %19.4 %
202076.24 %0 %0 %
201976.24 %0 %0 %
201821.24 %-2,047.79 %-2,388.5 %

RemeGen Co Stock Sales Revenue, EBIT, Earnings per Share

The RemeGen Co earnings per share therefore indicates how much revenue RemeGen Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue RemeGen Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates RemeGen Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of RemeGen Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating RemeGen Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

RemeGen Co Revenue, EBIT and net profit per share

DateRemeGen Co Sales per ShareRemeGen Co EBIT per shareRemeGen Co Earnings per Share
2029e12.54 undefined0 undefined0 undefined
2028e10.56 undefined0 undefined0 undefined
2027e8.22 undefined0 undefined0 undefined
2026e5.87 undefined0 undefined-0.28 undefined
2025e4.24 undefined0 undefined-1.56 undefined
2024e3.07 undefined0 undefined-2.6 undefined
20232.01 undefined-2.81 undefined-2.8 undefined
20221.45 undefined-2.02 undefined-1.88 undefined
20212.92 undefined0.49 undefined0.57 undefined
20200 undefined-1.64 undefined-1.71 undefined
20190 undefined-0.81 undefined-0.9 undefined
20180.02 undefined-0.48 undefined-0.56 undefined

RemeGen Co business model

RemeGen Co Ltd is a Chinese biotechnology company based in Yantai. The company was founded in 2008 by Dr. Li Zhu, who also developed the company's main product. RemeGen's goal is to develop innovative therapies for the treatment of cancer and autoimmune diseases. The company's business model involves researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. RemeGen works closely with leading researchers from around the world and conducts clinical trials to assess the safety and efficacy of its products. The company has various divisions focused on developing drugs for different diseases, including oncology, autoimmune diseases, and dermatology. RemeGen's flagship product is the antibody FGFR4, which is a new therapeutic agent for treating liver cancer. FGFR4 is one of the most highly expressed genes in liver cancer cells and plays a crucial role in tumor progression. The antibody inhibits the activity of FGFR4, thereby preventing the growth of liver cancer cells. Clinical studies have shown FGFR4 to be a promising treatment option for liver cancer, with positive results. In addition to FGFR4, RemeGen has other promising products in its development pipeline, including the antibody RC48, which is used in the treatment of advanced or metastatic lung cancer. RC48 targets the Epidermal Growth Factor Receptor (EGFR), a protein that is highly upregulated in many types of cancer and promotes the growth of cancer cells. Clinical studies have shown RC48 to be a promising treatment option for lung cancer, reaching Phase III. Overall, RemeGen Co Ltd has a promising approach to developing innovative drugs that have the potential to change the standard of care in oncology, autoimmune diseases, and dermatology. Through close collaboration with leading researchers and clinical trials, the company is well-positioned to further develop its pipeline and improve medical care for patients in China and worldwide. Answer: RemeGen Co Ltd is a Chinese biotechnology company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. It has a business model of researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. The company's divisions focus on oncology, autoimmune diseases, and dermatology. Its flagship product is the antibody FGFR4, which is used for treating liver cancer. RemeGen also has other promising products, such as the antibody RC48 for advanced lung cancer. The company's approach has the potential to change the standard of care in these medical fields. RemeGen Co is one of the most popular companies on Eulerpool.com.

RemeGen Co SWOT Analysis

Strengths

  • Strong Research and Development Capabilities
  • RemeGen Co Ltd possesses a robust research and development team that excels in creating innovative and effective pharmaceutical products. Their expertise and dedication enable the company to develop cutting-edge medicines to address critical medical conditions.
  • Diverse Product Portfolio
  • The company boasts a wide range of pharmaceutical products in various therapeutic areas. This diversified portfolio helps RemeGen Co Ltd capture a larger customer base and reduces its reliance on a single product or market segment.
  • Strong Market Presence in Domestic Market
  • RemeGen Co Ltd has established a strong presence in its domestic market. Their extensive distribution network, coupled with effective marketing strategies, has enabled them to capture a significant market share and maintain competitive advantages in their home country.

Weaknesses

  • Limited Global Market Penetration
  • Despite its success in the domestic market, RemeGen Co Ltd has yet to expand its presence significantly in international markets. Their limited global market penetration increases vulnerability to economic fluctuations or regulatory changes in the domestic market.
  • Reliance on External Manufacturing
  • The company relies on external manufacturing partners for a significant portion of its production capacity. This dependency introduces potential risks such as quality control issues, supply chain disruptions, and increased manufacturing costs.
  • Limited Brand Recognition
  • RemeGen Co Ltd faces a challenge in building strong brand recognition outside its domestic market. Limited brand awareness may hinder their ability to compete against well-established global pharmaceutical companies in international markets.

Opportunities

  • Expansion into Emerging Markets
  • With their strong product portfolio, RemeGen Co Ltd can consider entering emerging markets with high growth potential. Expanding into these markets can help diversify revenue sources, reduce reliance on the domestic market, and tap into new customer segments.
  • Strategic Partnerships and Collaborations
  • Forming strategic alliances and collaborations with other pharmaceutical companies can provide RemeGen Co Ltd with access to new technologies, markets, and resources. Such partnerships can enhance the company's capabilities, accelerate product development, and strengthen its competitive position.
  • Increased Focus on Research and Development
  • Investing further in research and development can enable RemeGen Co Ltd to continuously enhance its product pipeline and bring forth new breakthrough treatments. This focus on innovation can help the company maintain a competitive edge in the pharmaceutical industry.

Threats

  • Intense Competition in the Pharmaceutical Industry
  • RemeGen Co Ltd operates in a highly competitive environment characterized by the presence of both global pharmaceutical giants and local players. Intense competition can erode market share, lead to price pressures, and necessitate substantial marketing efforts to differentiate themselves.
  • Stringent Regulatory Requirements
  • The pharmaceutical industry faces rigorous regulations and strict compliance requirements, making it essential for RemeGen Co Ltd to stay up-to-date with changing regulations across markets. Non-compliance or delays in obtaining regulatory approvals can significantly impact product launches and revenue generation.
  • Economic Uncertainty
  • Economic uncertainties, such as recessions or financial crises, can impact consumer purchasing power and healthcare spending. RemeGen Co Ltd must navigate and adapt to changing economic conditions to ensure sustained demand for their products.

RemeGen Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

RemeGen Co historical P/E ratio, EBIT, and P/S ratio.

RemeGen Co shares outstanding

The number of shares was RemeGen Co in 2023 — This indicates how many shares 539.725 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue RemeGen Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates RemeGen Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of RemeGen Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating RemeGen Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for RemeGen Co.

RemeGen Co list of shareholders

%
Name
Stocks
Change
Date
5.14067 % Fang (Jianmin)27,718,3201,500,00012/31/2023
3.43240 % Yantai Rongqian Enterprise Management Center (L.P.)18,507,388012/31/2023
3.08428 % Yantai Rongyi Enterprise Management Center (L.P.)16,630,337012/31/2023
2.64528 % PAG Growth Prosperity Holding I (HK) Ltd.14,263,276012/31/2023
2.52227 % I-Nova Ltd.13,600,000012/31/2023
18.98785 % Yantai Rongda Venture Capital Center (L.P.)102,381,891012/31/2023
1.70442 % Yantai Rongshi Enterprise Management Center L.P.9,190,203012/31/2023
1.39802 % Beijing Longpan Health Medical Investment Centre L.P.7,538,084012/31/2023
1.33440 % Shenzhen Capital Group Co. Ltd.7,195,061-4,441,87212/31/2023
1.17469 % China Universal Asset Management Co., Ltd.6,333,9162,884,42612/31/2023
1
2
3
4
5
...
10

RemeGen Co Executives and Management Board

Mr. Jianmin Fang61
RemeGen Co Chief Executive Officer, Chief Scientific Officer, General Manager, Executive Director (since 2020)
Compensation 26.54 M
Mr. Ruyi He62
RemeGen Co Executive Director, Chief Medical Officer and Head of Clinical Research (since 2020)
Compensation 26.04 M
Mr. Daotian Fu60
RemeGen Co President
Compensation 3.64 M
Mr. Weidong Wang63
RemeGen Co Executive Chairman of the Board (since 2019)
Compensation 3.06 M
Mr. Qingkai Wen56
RemeGen Co Secretary of the Board
Compensation 1.73 M
1
2
3

Most common questions regarding RemeGen Co

What values and corporate philosophy does RemeGen Co represent?

RemeGen Co Ltd, a leading biopharmaceutical company, is guided by a strong set of values and corporate philosophy. With a focus on innovation, RemeGen strives to develop and deliver high-quality and cutting-edge therapies to improve the lives of patients. Their commitment to integrity and ethical practices forms the foundation of their operations. RemeGen embraces a patient-centric approach, ensuring that their products address significant medical needs and contribute to the well-being of individuals. By fostering collaboration and nurturing talent, RemeGen places great importance on teamwork and continuous learning. With these values and corporate philosophy, RemeGen Co Ltd remains dedicated to making a positive impact in the healthcare industry.

In which countries and regions is RemeGen Co primarily present?

RemeGen Co Ltd is primarily present in China.

What significant milestones has the company RemeGen Co achieved?

RemeGen Co Ltd has achieved several significant milestones in its journey. Firstly, the company successfully developed three innovative antibody-based drugs targeting cancer and autoimmune diseases. This breakthrough in biopharmaceutical research highlights RemeGen's commitment to advancing medical treatments. Additionally, the company gained approval for its leading drug, RC48, to treat metastatic or locally recurrent triple-negative breast cancer, a major accomplishment in the field. Moreover, RemeGen forged strategic partnerships with top global pharmaceutical companies, fostering collaborations for research, development, and commercialization of its drugs. These milestones underscore RemeGen Co Ltd's dedication to revolutionizing healthcare and cement its position as a trusted leader in the industry.

What is the history and background of the company RemeGen Co?

RemeGen Co Ltd is a renowned biopharmaceutical company founded in 2008, headquartered in Yantai, China. With a focus on research, development, and commercialization of innovative therapies, RemeGen has made significant strides in the field of oncology. The company aims to address unmet medical needs and revolutionize treatment options for patients worldwide. RemeGen Co Ltd has earned recognition for its robust pipeline of potential breakthrough drugs, leveraging their expertise in monoclonal antibodies, antibody-drug conjugates, and fusion proteins. Their commitment to scientific excellence and dedication to improving patients' lives have established RemeGen as a leading player in the biopharmaceutical industry.

Who are the main competitors of RemeGen Co in the market?

The main competitors of RemeGen Co Ltd in the market include a range of pharmaceutical companies operating in the same sector. Some notable competitors include BeiGene Ltd, Hengrui Medicine Co Ltd, and Junshi Biosciences Co Ltd. These companies, like RemeGen Co Ltd, are engaged in the research, development, and commercialization of innovative drugs and therapies. As a leading player in the pharmaceutical industry, RemeGen Co Ltd competes in various therapeutic areas, aiming to bring novel and effective treatments to the market.

In which industries is RemeGen Co primarily active?

RemeGen Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of RemeGen Co?

RemeGen Co Ltd is a biopharmaceutical company based in China. The business model of RemeGen Co Ltd primarily focuses on the research, development, and commercialization of innovative biologics for the treatment of various diseases. The company specializes in developing monoclonal antibodies and fusion proteins to target specific diseases, such as cancer and autoimmune disorders. RemeGen Co Ltd aims to provide effective and safe therapeutic options to patients in need, while also generating sustainable growth and creating value for its shareholders. With its dedication to advancing healthcare through biotechnology, RemeGen Co Ltd strives to positively impact patients' lives and contribute to the advancement of the global pharmaceutical industry.

What is the P/E ratio of RemeGen Co 2024?

The RemeGen Co P/E ratio is -4.47.

What is the P/S ratio of RemeGen Co 2024?

The RemeGen Co P/S ratio is 3.78.

What is the AlleAktien quality score of RemeGen Co?

The AlleAktien quality score for RemeGen Co is 3/10.

What is the revenue of RemeGen Co 2024?

The expected RemeGen Co revenue is 1.66 B CNY.

How high is the profit of RemeGen Co 2024?

The expected RemeGen Co profit is -1.4 B CNY.

What is the business model of RemeGen Co

The company RemeGen Co Ltd is a biopharmaceutical company based in China that specializes in the development and commercialization of novel therapeutic antibodies. The company was founded in 2008 and is one of the leading companies in the biopharmaceutical industry. RemeGen is working on the development of antibodies with high efficacy and low risk of side effects. The company has developed a comprehensive pipeline that includes clinical trials for a variety of diseases, including cancer, autoimmune diseases, viral infections, and inflammation. The company's main product is IBI310, a monoclonal antibody specifically designed for the treatment of cancer patients. IBI310 fights cancer cells by selectively binding to the surface protein PD-L1 and triggering an immune response that destroys the cancer cells. The drug has the potential to revolutionize the treatment of cancer patients and is already being tested in clinical trials. RemeGen also offers projects in the field of novel antibody therapy for autoimmune diseases. The company has developed a pipeline of several potential therapeutics targeting various target molecules involved in autoimmune diseases. The company is also focused on the development of drugs to combat viral infections such as hepatitis B and C, as well as HIV. RemeGen's goal is to defeat these diseases and provide patients with a better quality of life. RemeGen is also a leading provider of biopharmaceutical services that support customers in conducting their research and product development. The company offers a wide range of services ranging from antibody design and development to cell line development and production, as well as analysis and characterization. RemeGen's business model is based on collaboration with other biopharmaceutical companies to jointly develop more innovative and effective therapies. The company has established strong partnerships with leading pharmaceutical companies such as Pfizer, Merck, and Roche. RemeGen's experience and expertise in the field of biopharmaceutical research and development have contributed to its position as one of the leading companies in this field. The company is continuously working to improve medical care and enhance the quality of life for patients.

What is the RemeGen Co dividend?

RemeGen Co pays a dividend of 0 CNY distributed over payouts per year.

How often does RemeGen Co pay dividends?

The dividend cannot currently be calculated for RemeGen Co or the company does not pay out a dividend.

What is the RemeGen Co ISIN?

The ISIN of RemeGen Co is CNE1000048G6.

What is the RemeGen Co WKN?

The WKN of RemeGen Co is A2QGM4.

What is the RemeGen Co ticker?

The ticker of RemeGen Co is 9995.HK.

How much dividend does RemeGen Co pay?

Over the past 12 months, RemeGen Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RemeGen Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of RemeGen Co?

The current dividend yield of RemeGen Co is .

When does RemeGen Co pay dividends?

RemeGen Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RemeGen Co?

RemeGen Co paid dividends every year for the past 0 years.

What is the dividend of RemeGen Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is RemeGen Co located?

RemeGen Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von RemeGen Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RemeGen Co from 9/13/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did RemeGen Co pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of RemeGen Co in the year 2023?

In the year 2023, RemeGen Co distributed 0 CNY as dividends.

In which currency does RemeGen Co pay out the dividend?

The dividends of RemeGen Co are distributed in CNY.

All fundamentals about RemeGen Co

Our stock analysis for RemeGen Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RemeGen Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.